NRG1 fusions in breast cancer

by Karen D. Howarth, Tashfina Mirza, Susanna L. Cooke, Suet-Feung Chin, Jessica C. Pole, Ernest Turro, Matthew D. Eldridge, Raquel Manzano Garcia, Oscar M. Rueda, Chris Boursnell, Jean E. Abraham, Carlos Caldas, Paul A. W. Edwards
Published 2021-01-01

The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study.

by Leila Dorling, Siddhartha Kar, Kyriaki Michailidou, Louise Hiller, Anne-Laure Vallier, Susan Ingle, Richard Hardy, Sarah J Bowden, Janet A Dunn, Chris Twelves, Christopher J Poole, Carlos Caldas, Helena M Earl, Paul D P Pharoah, Jean E Abraham
Published 2016-01-01

Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

by Helena Earl, Louise Hiller, Anne-Laure Vallier, Shrushma Loi, Karen McAdam, Luke Hughes-Davies, Daniel Rea, Donna Howe, Kerry Raynes, Helen B Higgins, Maggie Wilcox, Chris Plummer, Betania Mahler-Araujo, Elena Provenzano, Anita Chhabra, Sophie Gasson, Claire Balmer, Jean E Abraham, Carlos Caldas, Peter Hall, Bethany Shinkins, Christopher McCabe, Claire Hulme, David Miles, Andrew M Wardley, David A Cameron, Janet A Dunn
Published 2020-08-01